Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vistagen Therapeutics, Inc. - Common Stock
(NQ:
VTGN
)
0.6867
+0.0011 (+0.16%)
Streaming Delayed Price
Updated: 10:24 AM EST, Jan 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vistagen Therapeutics, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
March 22, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Provides Update on Phase 1 Clinical Trial of Proprietary PH10
March 09, 2023
Via
Investor Brand Network
VistaGen Therapeutics's Return On Capital Employed Insights
↗
February 09, 2023
Via
Benzinga
VistaGen Shares Plunge Amid Uncertainty Around Its Anxiety Trial
↗
February 08, 2023
Via
Benzinga
Preview: VistaGen Therapeutics's Earnings
↗
February 06, 2023
Via
Benzinga
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
March 08, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Upcoming Health Care Conference
March 02, 2023
Via
Investor Brand Network
Vistagen to Present at Cowen 43rd Annual Health Care Conference
March 02, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Secures US Patent for PH80 Nasal Spray for Treatment of Migraine
March 01, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
March 01, 2023
From
Vistagen
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
February 14, 2023
It's time to start another day of trading with a breakdown of the biggest pre-market stock movers investors need to watch for Tuesday!
Via
InvestorPlace
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
February 13, 2023
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
February 10, 2023
Via
Benzinga
Why Alteryx Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
↗
February 10, 2023
Gainers
Via
Benzinga
Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
February 10, 2023
Gainers SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
February 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
February 08, 2023
Via
Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2023 Financial Results, Corporate Update
February 08, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
February 08, 2023
Via
Benzinga
Why Sintx Technologies Shares Are Trading Lower By 38%; Here Are 20 Stocks Moving Premarket
↗
February 08, 2023
Gainers PainReform Ltd. (NASDAQ: PRFX) shares rose 89.5% to $0.9475 in pre-market trading. PainReform reported receipt of extension to Aug. 7, 2023 to meet the Nasdaq's minimum bid price requirement.
Via
Benzinga
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
February 07, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Q3 Fiscal 2023 Results Call and Webcast
February 06, 2023
Via
Investor Brand Network
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
February 06, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Closing of Strategic Acquisition
February 02, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
February 02, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Doses First Participants in PH10 Phase 1 Clinical Trial
January 24, 2023
Via
Investor Brand Network
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
January 31, 2023
Gainers
Via
Benzinga
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
January 24, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Set to Commence Antidepressant Nasal Spray Trial This Quarter
January 19, 2023
Via
Investor Brand Network
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
January 19, 2023
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
Via
News Direct
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
